中国全科医学2012，Vol.15Issue(9)：987-989,3.
吉西他滨联合顺铂在非小细胞肺癌辅助化疗中的应用
Application of Gemcitabine Combined with Cisplatin in Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
王静 1李峻岭 1石远凯 1张湘茹 1王燕 1郝学志 1王彬 1许建萍1
作者信息
- 1. 100021,北京市,北京协和医学院中国医学科学院肿瘤医院肿瘤研究所
- 折叠
摘要
Abstract
Objective To evaluate efficacy and toxicity of gemcitabine combined with cisplatin as adjuvant chemotherapy in non - small cell lung cancer. Methods Clinical data of 100 NSCLC patients admitted to our hospital who received adjuvant chemotherapy of gemcitabine combined with cisplatin were retrospectively analyzed. Results 372 chemotherapy cycles were completed among 100 patients, and the median chemotherapy cycle was 4. The completion rate of 4 cycles was 85% , with 76 cases ( 76% ) completing full dose chemotherapy. The median dose and median dose intensity of gemcitabine were 8 377. 1 mg/m and 708 mg ? M-2 ? W-1 respectively;the median dose and median dose intensity of cisplatin were 293. 38 mg/m2 and 25. 24 mg ? M~ ? W respectively. Hematological toxicities over grade Ⅲ were granulocytopenia ( 27. 5% ), thrombocytopenia ( 9. 9% ), neutropenia ( 9. 0% ) and anemia ( 1. 1% ) . During the 2. 40 to 46. 72 months following up, 5 patients died, all being IH A stage cases. 74 cases were followed up more than one year, and one year recurrence - free survival rate was 78. 4% ;21 cases were followed up more two years, and two year recurrence - free survival rate was 85. 7%. Conclusion The combination of cisplatin and gemcitabine is of low toxicity and well - tolerated in the adjuvant treatment with high disease control rate in one or two years. However, we need further data of 5 year survival and recurrence free survival rate to support the efficacy.关键词
癌,非小细胞肺癌/吉西他滨/顺铂/抗肿瘤联合化疗方案Key words
Carcinoma, non - small - cell lung/Gemcitabine/Cisplatin/Antineoplastic combined chemotherapy protocds分类
医药卫生引用本文复制引用
王静,李峻岭,石远凯,张湘茹,王燕,郝学志,王彬,许建萍..吉西他滨联合顺铂在非小细胞肺癌辅助化疗中的应用[J].中国全科医学,2012,15(9):987-989,3.
